{"schema_version":"secwatch.filing_event.v1","accession":"0001096906-22-000524","form_type":"8-K","ticker":"AXIM","cik":"0001514946","company_name":"AXIM BIOTECHNOLOGIES, INC.","filed_at":"2022-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.815668+00:00","generated_at":"2026-06-27T00:21:59.311202+00:00","sec_items":["1.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"AXIM shifts COVID-19 NAb test to RUO; separates from Empowered Diagnostics","bullets":["COVID-19 NAb test now offered For Research Use Only after FDA changed priorities from qualitative testing.","Entered separation agreement with Empowered Diagnostics, LLC following FDA recall of their products.","Two RUO tests available: quantitative (exact number) and semi-quantitative (high/medium/low titers).","Partner Dr. Lake conducting ongoing correlative study at ASU on vaccine vs natural immunity NAb levels."],"urls":{"canonical":"https://secwatch.observer/filing/0001096906-22-000524","json":"https://secwatch.observer/filing/0001096906-22-000524.json","markdown":"https://secwatch.observer/filing/0001096906-22-000524.md","text":"https://secwatch.observer/filing/0001096906-22-000524.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514946/000109690622000524/0001096906-22-000524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514946/000109690622000524/axim-20220307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:21:59.311202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}